menu
    • menu

    Company profile for La Jolla Pharmaceutical

    NEW Drugs in Dev: 4
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    La Jolla PharmaceuticalUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4550 Towne Centre Court San Diego, California 92121
    Telephone
    Telephone
    (858) 207-4264
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lajollapharmaceutical.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BioAsia

    Not Confirmed

    envelop Contact Supplier

    BioAsia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    La Jolla Announces Data on XERAVA to be Presented at IDWeek 2022
    La Jolla Announces Data on XERAVA to be Presented at IDWeek 2022

    14 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221014005417/en

    BUSINESSWIRE
    14 Oct 2022
    Share Share
    Innoviva Completes Acquisition of La Jolla Pharmaceutical
    Innoviva Completes Acquisition of La Jolla Pharmaceutical

    22 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220821005020/en

    BUSINESSWIRE
    22 Aug 2022
    Share Share
    La Jolla Institute for Immunology Acquires the Carterra LSA Platform
    La Jolla Institute for Immunology Acquires the Carterra LSA Platform

    01 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220801005365/en/La-Jolla-Institute-for-Immunology-Acquires-the-Carterra-LSA-Platform-to-Advance-State-of-the-Art-Immunological-and-Infectious-Disease-Research

    BUSINESSWIRE
    01 Aug 2022
    Share Share
    Innoviva to Acquire La Jolla Pharmaceutical Company
    Innoviva to Acquire La Jolla Pharmaceutical Company

    11 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220711005314/en

    BUSINESSWIRE
    11 Jul 2022
    Share Share
    La Jolla Announces Financial Results for 3 Months Ended March 31, 2022
    La Jolla Announces Financial Results for 3 Months Ended March 31, 2022

    16 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220516005125/en

    BUSINESSWIRE
    16 May 2022
    Share Share
    La Jolla Announces Financial Results for 3 and 12 Months Ended December 31, 2021
    La Jolla Announces Financial Results for 3 and 12 Months Ended December 31, 2021

    09 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220309005270/en

    BUSINESSWIRE
    09 Mar 2022
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact La Jolla Pharmaceutical and get a quotation

    La Jolla Pharmaceutical is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of LJP 394 DRUG SUBSTANCE bulk offered by La Jolla Pharmaceutical

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search